{"id":19577,"date":"2021-05-13T18:01:04","date_gmt":"2021-05-13T12:31:04","guid":{"rendered":"http:\/\/udaen.info\/?p=19577"},"modified":"2021-05-13T18:01:04","modified_gmt":"2021-05-13T12:31:04","slug":"pibs-bulletin-on-covid-19-4","status":"publish","type":"post","link":"https:\/\/udaen.info\/?p=19577","title":{"rendered":"PIB\u2019S BULLETIN ON COVID-19"},"content":{"rendered":"<p style=\"font-weight: 400;\">PIB Headquarters<\/p>\n<h2 style=\"font-weight: 500;\">PIB\u2019S BULLETIN ON COVID-19<\/h2>\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<table style=\"font-weight: 400;\">\n<tbody>\n<tr>\n<td>\n<ul>\n<li><b><strong>India\u2019s Cumulative Vaccination Coverage exceeds 17.72 Crore<\/strong><\/b><\/li>\n<li><b><strong>More than Half a Crore patients served by the National Telemedicine Service (eSanjeevani) during the COVID-19 Pandemic<\/strong><\/b><\/li>\n<li><b><strong>DCGI approves Phase II\/III clinical trial of COVAXIN in the age group of 2 to 18 Years<\/strong><\/b><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 style=\"font-weight: 500;\"><\/h2>\n<h2 style=\"font-weight: 500;\"><\/h2>\n<h2 style=\"font-weight: 500;\">#Unite2FightCorona<\/h2>\n<h2 style=\"font-weight: 500;\">#IndiaFightsCorona<\/h2>\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<h2 style=\"font-weight: 500;\">PRESS INFORMATION BUREAU<\/h2>\n<h2 style=\"font-weight: 500;\">MINISTRY OF INFORMATION AND BROADCASTING<\/h2>\n<h2 style=\"font-weight: 500;\">GOVERNMENT OF INDIA<\/h2>\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\"><b><strong><u>India\u2019s Cumulative Vaccination Coverage exceeds 17.72 Crore<\/u><\/strong><\/b><\/p>\n<ul style=\"font-weight: 400;\">\n<li><b><strong>4,31,285\u00a0<\/strong><\/b>beneficiaries of the age group 18-44 years received their first dose of COVID vaccine in the last 24 hours and cumulatively\u00a0<b><strong>34,80,618\u00a0<\/strong><\/b>across 30 States\/UTs since the start of phase-3 of vaccination drive. Table below shows the cumulative vaccine doses administered to 18-44 years age group till now.<\/li>\n<li>India\u2019s cumulative recoveries stand at\u00a0<b><strong>1,97,34,823\u00a0<\/strong><\/b>today. The National Recovery Rate\u00a0is\u00a0<b><strong>83.26%.<\/strong><\/b><\/li>\n<li>The National Mortality Rate currently stands at\u00a0<b><strong>1.09%.<\/strong><\/b><\/li>\n<\/ul>\n<p style=\"font-weight: 400;\">For Details :\u00a0<a href=\"https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718217\">https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718217<\/a><\/p>\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\"><b><strong><u>More than Half a Crore patients served by the National Telemedicine Service (eSanjeevani) during the COVID-19Pandemic<\/u><\/strong><\/b><\/p>\n<ul style=\"font-weight: 400;\">\n<li>Daily, over 1500 doctors serve patients remotely through eSanjeevani telemedicine platform<\/li>\n<li>Few States working towards rolling out special Home Isolation OPDs wherein patients can be screened remotely for COVID-19 by final year MBBS students<\/li>\n<\/ul>\n<p style=\"font-weight: 400;\">For Details:\u00a0<a href=\"https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718221\">https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718221<\/a><\/p>\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\"><b><strong><u>DCGI approves Phase II\/III clinical trial of COVAXIN in the age group of 2 to 18 Years<\/u><\/strong><\/b><\/p>\n<p style=\"font-weight: 400;\">The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II\/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat Biotech Ltd on 12.05.2021.<\/p>\n<p style=\"font-weight: 400;\">For Details:\u00a0<a href=\"https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718192\">https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718192<\/a><\/p>\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\"><b><strong><u>Update on Ventilators Supplied under PM CARES<\/u><\/strong><\/b><\/p>\n<p style=\"font-weight: 400;\">\u201cMade in India\u201d Ventilators have strengthened Infrastructure of Hospitals for Effective COVID management. All Technical Assistance being provided by Manufacturers for their Glitch-free Operation.<\/p>\n<p style=\"font-weight: 400;\">For Details:\u00a0<a href=\"https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718183\">https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718183<\/a><\/p>\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\"><b><strong><u>Bhubaneswar Airport ensures seamless delivery of medical essentials to support the fight against Covid-19<\/u><\/strong><\/b><\/p>\n<p style=\"font-weight: 400;\">Total 156 empty oxygen tankers, 526 oxygen concentrators and 140 oxygen cylinders transported.\n<\/p>\n<p style=\"font-weight: 400;\">For Details:\u00a0<a href=\"https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718233\">https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1718233<\/a><\/p>\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\"><b><strong><u>PIB FACT CHECK<\/u><\/strong><\/b><\/p>\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n<p style=\"font-weight: 400;\">\n","protected":false},"excerpt":{"rendered":"<p>PIB Headquarters PIB\u2019S BULLETIN ON COVID-19 India\u2019s Cumulative Vaccination Coverage exceeds 17.72 Crore More than Half a Crore patients served by the National Telemedicine Service (eSanjeevani) during the COVID-19 Pandemic DCGI approves Phase II\/III clinical trial of COVAXIN in the age group of 2 to 18 Years #Unite2FightCorona #IndiaFightsCorona PRESS INFORMATION BUREAU MINISTRY OF INFORMATION [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_monsterinsights_skip_tracking":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[1],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/19577"}],"collection":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19577"}],"version-history":[{"count":2,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/19577\/revisions"}],"predecessor-version":[{"id":19600,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/19577\/revisions\/19600"}],"wp:attachment":[{"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}